167 related articles for article (PubMed ID: 29506127)
1. Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages.
Voak AA; Standing JF; Sepúlveda N; Harris A; Croft SL; Seifert K
J Antimicrob Chemother; 2018 May; 73(5):1314-1323. PubMed ID: 29506127
[TBL] [Abstract][Full Text] [Related]
2. Using a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular Leishmania amastigotes.
Paape D; Bell AS; Heal WP; Hutton JA; Leatherbarrow RJ; Tate EW; Smith DF
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3363. PubMed ID: 25522361
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert K; Croft SL
Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.
Vermeersch M; da Luz RI; Toté K; Timmermans JP; Cos P; Maes L
Antimicrob Agents Chemother; 2009 Sep; 53(9):3855-9. PubMed ID: 19546361
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent.
Seifert K; Escobar P; Croft SL
J Antimicrob Chemother; 2010 Mar; 65(3):508-11. PubMed ID: 20089542
[TBL] [Abstract][Full Text] [Related]
6. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
Vishwakarma P; Parmar N; Yadav PK; Chandrakar P; Kar S
J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.
Voak AA; Harris A; Coteron-Lopez JM; Angulo-Barturen I; Ferrer-Bazaga S; Croft SL; Seifert K
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009013. PubMed ID: 33651812
[TBL] [Abstract][Full Text] [Related]
8. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Escobar P; Yardley V; Croft SL
Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
[TBL] [Abstract][Full Text] [Related]
9. In vitro 4-Aryloxy-7-chloroquinoline derivatives are effective in mono- and combined therapy against Leishmania donovani and induce mitocondrial membrane potential disruption.
Valdivieso E; Mejías F; Torrealba C; Benaim G; Kouznetsov VV; Sojo F; Rojas-Ruiz FA; Arvelo F; Dagger F
Acta Trop; 2018 Jul; 183():36-42. PubMed ID: 29604246
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of antileishmanial drugs activities in an ex vivo model of leishmaniasis.
Terreros MJS; de Luna LAV; Giorgio S
Parasitol Int; 2019 Aug; 71():163-166. PubMed ID: 30991111
[TBL] [Abstract][Full Text] [Related]
11. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.
Wadhone P; Maiti M; Agarwal R; Kamat V; Martin S; Saha B
J Immunol; 2009 Jun; 182(11):7146-54. PubMed ID: 19454711
[TBL] [Abstract][Full Text] [Related]
12. A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani.
Tegazzini D; Díaz R; Aguilar F; Peña I; Presa JL; Yardley V; Martin JJ; Coteron JM; Croft SL; Cantizani J
Antimicrob Agents Chemother; 2016 Jun; 60(6):3524-32. PubMed ID: 27021313
[TBL] [Abstract][Full Text] [Related]
13. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani.
Zahid MSH; Johnson MM; Tokarski RJ; Satoskar AR; Fuchs JR; Bachelder EM; Ainslie KM
Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():125-132. PubMed ID: 31493763
[TBL] [Abstract][Full Text] [Related]
15. Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro.
Das S; Rani M; Pandey K; Sahoo GC; Rabidas VN; Singh D; Das P
J Antimicrob Chemother; 2012 Oct; 67(10):2373-8. PubMed ID: 22761329
[TBL] [Abstract][Full Text] [Related]
16. Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosine.
Tegazzini D; Cantizani J; Peña I; Martín J; Coterón JM
PLoS Negl Trop Dis; 2017 May; 11(5):e0005629. PubMed ID: 28542202
[TBL] [Abstract][Full Text] [Related]
17. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.
Escobar P; Matu S; Marques C; Croft SL
Acta Trop; 2002 Feb; 81(2):151-7. PubMed ID: 11801222
[TBL] [Abstract][Full Text] [Related]
18. Aspects of the cytological activity of edelfosine, miltefosine, and ilmofosine in Leishmania donovani.
Azzouz S; Maache M; Dos Santos MF; Sarciron ME; Petavy AF; Osuna A
J Parasitol; 2006 Oct; 92(5):877-83. PubMed ID: 17152926
[TBL] [Abstract][Full Text] [Related]
19. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.
Jain SK; Sahu R; Walker LA; Tekwani BL
J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299097
[TBL] [Abstract][Full Text] [Related]
20. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Deep DK; Singh R; Bhandari V; Verma A; Sharma V; Wajid S; Sundar S; Ramesh V; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005641. PubMed ID: 28575060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
